Overview

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

Status:
Not yet recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
ModernaTX, Inc.